Boardroom Alpha
Boardroom Alpha
AMGN · Additional Proxy Materials (DEFA14A) · Filed April 7, 2026

Amgen Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 7, 2026
Ticker
AMGN
Accession
0001193125-26-145596
Boardroom Alpha · Filing insights

Amgen urges vote for its 12-director slate, supports compensation and audit ratification, opposes independent-chair proposal.

About Amgen Inc
Market cap
$177.2B
1Y TSR
+18.8%
3Y TSR
+17.7%
Board grade
B
Sector
Healthcare
CEO
Robert A Bradway
Last annual meeting: May 19, 2026 · View full Amgen Inc profile →
DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 Filed by the registrant     

 Filed by a party other than the registrant

 

Check the appropriate box:

 

 

 

Preliminary Proxy Statement

 

 

 

CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2))

 

 

 

Definitive Proxy Statement

 

 

 

Definitive Additional Materials

 

 

 

Soliciting Material Pursuant to Section 240.14a-12

 

 

AMGEN INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of filing fee (check the appropriate box):

 

 

 

No fee required.

 

 

 

Fee paid previously with preliminary materials.

 

 

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 


 

img35496808_0.jpg

 


 

Sample Your Vote Counts! AMGEN INC. 2026 Annual Meeting Vote by May 18, 2026 11:59 PM ET for shares held directly. For shares held in plans sponsored by Amgen or its subsidiaries, vote by May 14, 2026 11:59 PM ET. AMGEN INC. ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320-1799 ATTN: CORPORATE SECRETARY V91788-P49460 You invested in AMGEN INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 19, 2026. Get informed before you vote View the Notice of 2026 Annual Meeting of Stockholders, Proxy Statement, and 2025 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 5, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 19, 2026 11:00 A.M., Pacific Time For holders as of: March 20, 2026 Virtually at: www.virtualshareholdermeeting.com/AMGN2026 The Amgen Inc. 2026 Annual Meeting of Stockholders will be held solely by remote communication via the Internet. Although the Annual Meeting will not be held in person, stockholders will, to the extent possible, be afforded the same rights and opportunities to participate at the virtual meeting similarly to how they would participate at an in-person meeting. *Please check the meeting materials for any special requirements for meeting attendance.

 

 


 

img35496808_1.jpg

 


 

Sample Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. More complete proxy materials, which contain important information, are available on the Internet or by mail. Please follow the instructions on the reverse side to access and review the complete proxy materials before voting and to vote these important matters. Board Voting Items Recommends 1.To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: 1a.Dr. Wanda M. AustinFor1b.Mr. Robert A. BradwayFor1c.Dr. Michael V. DrakeFor1d.Dr. Brian J. DrukerFor1e.Mr. Robert A. EckertFor1f.Mr. Greg C. GarlandFor1g.Mr. Charles M. Holley, Jr.For1h.Dr. S. Omar IshrakFor1i.Dr. Tyler JacksFor1j.Dr. Mary E. KlotmanFor1k.Ms. Ellen J. KullmanFor1l.Ms. Amy E. MilesFor2.Advisory vote to approve our executive compensation.For3.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2026.For4.Stockholder proposal to require an independent board chairman. Against NOTE: Such other business as may properly come before the meeting or any continuation, postponement, or adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V91789-P49460

 


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Amgen Inc (AMGN)

Reference

Frequently asked questions

When did Amgen Inc file this DEFA14A?
Amgen Inc (AMGN) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 7, 2026. The accession number assigned by EDGAR is 0001193125-26-145596.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Amgen urges vote for its 12-director slate, supports compensation and audit ratification, opposes independent-chair proposal. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Amgen Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Amgen Inc has filed under CIK 318154, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer